Jundishapur Journal of Microbiology

Published by: Kowsar

Serum Levels of Soluble CD26, A Novel Prognostic Marker for Hepatitis E Infection

Alireza Rafiei 1 , Abolghasem Ajami 1 , Araz Mohammad Mirabi 2 , * , Mohammad Jafar Saffar 3 , Omolbanin Amjadi 1 , Mohammad Reza Haghshenas 4 , Farshideh Abedian 2 and Pouya Khaje-Enayati 5
Authors Information
1 Molecular and Cell Biology Research Center, Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
2 Department of Immunology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Department of Infectious Diseases, Buali Hospital, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
4 Molecular and Cell Biology Research Center, Department of Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
5 Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Jundishapur Journal of Microbiology: February 01, 2016, 9 (2); e31110
  • Published Online: February 15, 2016
  • Article Type: Research Article
  • Received: July 19, 2015
  • Revised: November 11, 2015
  • Accepted: December 1, 2015
  • DOI: 10.5812/jjm.31110

To Cite: Rafiei A, Ajami A, Mohammad Mirabi A, Saffar M J, Amjadi O, et al. Serum Levels of Soluble CD26, A Novel Prognostic Marker for Hepatitis E Infection, Jundishapur J Microbiol. 2016 ; 9(2):e31110. doi: 10.5812/jjm.31110.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Pringle CR. Virus taxonomy--San Diego 1998. Arch Virol. 1998; 143(7): 1449-59[PubMed]
  • 2. Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol. 2003; 13(3): 145-54[DOI][PubMed]
  • 3. Pischke S, Wedemeyer H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem? Minerva Gastroenterol Dietol. 2010; 56(2): 121-8[PubMed]
  • 4. Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol. 2009; 24(9): 1484-93[DOI][PubMed]
  • 5. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008; 14(4): 547-53[DOI][PubMed]
  • 6. Pal R, Aggarwal R, Naik SR, Das V, Das S, Naik S. Immunological alterations in pregnant women with acute hepatitis E. J Gastroenterol Hepatol. 2005; 20(7): 1094-101[DOI][PubMed]
  • 7. Maylin S, Stephan R, Molina JM, Peraldi MN, Scieux C, Nicand E, et al. Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised. J Clin Virol. 2012; 53(4): 346-9[DOI][PubMed]
  • 8. Liu L, Liu Y. Analysis of acute to chronic hepatitis E: 6-10 year follow-up. Hepato-gastroenterology. 2010; 58(106): 324-5
  • 9. Shata MT, Barrett A, Shire NJ, Abdelwahab SF, Sobhy M, Daef E, et al. Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay. J Immunol Methods. 2007; 328(1-2): 152-61[DOI][PubMed]
  • 10. Srivastava R, Aggarwal R, Jameel S, Puri P, Gupta VK, Ramesh VS, et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol. 2007; 20(1): 56-65[DOI][PubMed]
  • 11. Aggarwal R, Shukla R, Jameel S, Agrawal S, Puri P, Gupta VK, et al. T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat. 2007; 14(4): 283-92[DOI][PubMed]
  • 12. Husain MM, Aggarwal R, Kumar D, Jameel S, Naik S. Effector T cells immune reactivity among patients with acute hepatitis E. J Viral Hepat. 2011; 18(10)-8[DOI][PubMed]
  • 13. Krakauer M, Sorensen PS, Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol. 2006; 181(1-2): 157-64[DOI][PubMed]
  • 14. Mosmann TR, Coffman RL. Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T Cells. Adv Immunol. 1989; 46: 111-47[DOI]
  • 15. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol. 1995; 57(5): 726-30
  • 16. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995; 9(1): 81-6[PubMed]
  • 17. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts). Clin Ter. 2006; 157(5): 457-68[PubMed]
  • 18. Yang SS, Fu LS, Chang CS, Yeh HZ, Chen GH, Kao JH. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006; 21(12): 1789-93[DOI][PubMed]
  • 19. Ajdary S, Jafari-Shakib R, Riazi-Rad F, Khamesipour A. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis. J Infect. 2007; 55(1): 75-8[DOI]
  • 20. Monsalve-de Castillo F, Romero TA, Estevez J, Costa LL, Atencio R, Porto L, et al. Concentrations of Cytokines, Soluble Interleukin-2 Receptor, and Soluble CD30 in Sera of Patients with Hepatitis B Virus Infection during Acute and Convalescent Phases. Clin Vaccine Immunol. 2002; 9(6): 1372-5[DOI]
  • 21. Foschi FG, Gramenzi A, Castelli E, Cursaro C, Pagani S, Margotti M, et al. Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity? Cytokine. 2000; 12(6): 815-8[DOI][PubMed]
  • 22. Tripathy AS, Das R, Rathod SB, Arankalle VA. Cytokine profiles, CTL response and T cell frequencies in the peripheral blood of acute patients and individuals recovered from hepatitis E infection. PLoS One. 2012; 7(2)[DOI][PubMed]
  • 23. Saffar MJ, Farhadi R, Ajami A, Khalilian AR, Babamahmodi F, Saffar H. Seroepidemiology of hepatitis E virus infection in 2-25-year-olds in Sari district, Islamic Republic of Iran. East Mediterr Health J. 2009; 15(1): 136-42
  • 24. Okamoto H. Culture systems for hepatitis E virus. J Gastroenterol. 2013; 48(2): 147-58[DOI][PubMed]
  • 25. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS. 1995; 103(3): 161-79[PubMed]
  • 26. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264(5167): 1918-21[PubMed]
  • 27. Mishra N, Arankalle VA. Association of polymorphisms in the promoter regions of TNF-alpha (-308) with susceptibility to hepatitis E virus and TNF-alpha (-1031) and IFN-gamma (+874) genes with clinical outcome of hepatitis E infection in India. J Hepatol. 2011; 55(6): 1227-34[DOI][PubMed]
  • 28. Krain LJ, Nelson KE, Labrique AB. Host immune status and response to hepatitis E virus infection. Clin Microbiol Rev. 2014; 27(1): 139-65[DOI][PubMed]
  • 29. Jiang R, Feng X, Guo Y, Lu Q, Hou J, Luo K, et al. T helper cells in patients with chronic hepatitis B virus infection. China Med J. 2002; 115(3): 422-4
  • 30. Suneetha PV, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert A, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology. 2012; 55(3): 695-708[DOI][PubMed]
  • 31. Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology. 1997; 25(4): 1022-7[DOI][PubMed]
  • 32. TrehanPati N, Sukriti S, Geffers R, Hissar S, Riese P, Toepfer T, et al. Gene expression profiles of T cells from hepatitis E virus infected patients in acute and resolving phase. J Clin Immunol. 2011; 31(3): 498-508[DOI][PubMed]
  • 33. Saravanabalaji S, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle VA. Viral load, antibody titers and recombinant open reading frame 2 protein-induced TH1/TH2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis e. Intervirology. 2009; 52(2): 78-85[DOI][PubMed]
  • 34. Hoshimoto K, Ohta N, Ohkura T, Inaba N. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance? Gynecol Obstet Invest. 2000; 50(4): 260-3[PubMed]
  • 35. Nakao K, Nagake Y, Okamoto A, Ichikawa H, Yamamura M, Makino H. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron. 2002; 91(2): 215-21[PubMed]
  • 36. Prabhu SB, Gupta P, Durgapal H, Rath S, Gupta SD, Acharya SK, et al. Study of cellular immune response against Hepatitis E virus (HEV). J Viral Hepat. 2011; 18(8): 587-94[DOI][PubMed]
  • 37. Alavi-Moghaddam M, Alavian SM, Aalaei-Andabili SH, Eslami-Far A. Do the initial serum level changes of sCD26 have ability to predict successful treatment with IFN-alpha among naive chronic hepatitis B patients? Vaccine. 2011; 29(48): 9093-7[DOI][PubMed]
  • 38. Schonermarck U, Csernok E, Trabandt A, Hansen H, Gross WL. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol. 2000; 18(4): 457-63[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments